Market Cap: $11.26B
BC
Bio-Techne Corporation
TECH
NASDAQUSD
Market Cap: $11.26B
Bio-Techne (TECH) has recently forged a significant collaboration with Refeyn to advance the analysis of bispecific antibodies and biosimilars. This partnership is set to introduce an innovative four-…
Earlier this week, Bio-Techne (Ticker: TECH) and Refeyn announced a transformative partnership aimed at revolutionizing the characterization process of bispecific antibodies and biosimilars in biotech…
Bio-Techne (Ticker: TECH) unveils a groundbreaking workflow aimed at transforming the characterization of bispecific antibodies and biosimilars. This innovative approach combines Bio-Techne's R&D Syst…
Bio-Techne Reinforces Commitment to Life Sciences Through Upcoming Conferences Bio-Techne Corporation, a prominent player in the global life sciences industry, actively engages with the investment com…
Stabilizing sales and stronger margins underpin Bio‑Techne’s near-term strategy Bio‑Techne posts a quarter of steady revenue and improving profitability as it leans on cost programs and regional execu…
Lawmakers and Private Investments: A Delicate Balance in Biotechnology A recent stock acquisition by Representative April McClain Delaney raises significant questions about the ethical boundaries betw…
Regulatory Scrutiny Surrounds Lawmaker's Investment in Bio-Techne A recent report reveals that Representative April McClain Delaney purchased shares of Bio-Techne, a prominent biotechnology company, o…
Bio-Techne Partners with Wyss Center to Advance Multiomic Analysis in 3D Tissue Specimens Bio-Techne Corporation has forged a strategic alliance with the Wyss Center for Bio and Neuroengineering in Ge…
Bio-Techne Partners with Wyss Center to Advance Multiomic Analysis in 3D Tissue Specimens Bio-Techne Corporation, a prominent player in life science tools and diagnostic products, announces a strategi…
Bio-Techne Strengthens Industry Presence Through Strategic Engagements Bio-Techne Corporation, a prominent player in the global life sciences sector, actively enhances its visibility and engagement wi…
Bio-Techne and Nucleai Forge New Path in Melanoma Treatment with SECOMBIT Trial Findings Bio-Techne Corporation, a leader in the life sciences sector, collaborates with Nucleai to present pivotal data…
Bio-Techne Partners in Innovative Grant to Accelerate Treg Therapy Development On November 3, 2025, Bio-Techne Corporation plays a pivotal role in the advancement of gene-modified regulatory T cell (T…
Bio-Techne Advances Gene Therapy Manufacturing with G-Rex® Grant for Sonoma Biotherapeutics In a significant development for the biotechnology sector, Bio-Techne Corporation, in collaboration with Sca…
Bio-Techne Fuels Advancements in Pediatric Oncology Through G-Rex Grants Bio-Techne Corporation, a prominent player in the biotechnology sector, actively contributes to the development of cell and gen…
Bio-Techne Drives Innovation in Pediatric Oncology with G-Rex Grants Bio-Techne Corporation plays a significant role in advancing cell and gene therapy initiatives, particularly in pediatric oncology,…
Bio-Techne Expands Collaboration with Oxford Nanopore to Enhance Genetic Testing Solutions Bio-Techne Corporation, a prominent entity in life science tools and diagnostics, significantly broadens its…
Bio-Techne Strengthens Genetic Testing Collaboration with Oxford Nanopore Technologies Bio-Techne Corporation enhances its strategic partnership with Oxford Nanopore Technologies, broadening its comme…
Bio-Techne Strengthens Genetic Testing Capabilities Through Enhanced Collaboration with Oxford Nanopore Technologies Bio-Techne Corporation, a prominent player in the life sciences sector, recently so…
Bio-Techne Advances Spatial Biology with New Technologies at NSH Convention Bio-Techne Corporation, a prominent player in life science tools, introduces significant advancements in its spatial biology…
Bio-Techne Advances Spatial Biology with Cutting-Edge Technology Bio-Techne Corporation, a frontrunner in providing life science tools, announces significant enhancements to its spatial biology offeri…
Bio-Techne Partners in Groundbreaking Cell Therapy Initiative In a significant move to enhance California's position in the field of cell and gene therapy (CGT) manufacturing, Bio-Techne Corporation c…
Bio-Techne's Role in Advancing Cell and Gene Therapy Through G-Rex Grants Bio-Techne Corporation significantly contributes to the field of cell and gene therapy (CGT) manufacturing, as evidenced by it…
Bio-Techne’s Resilience in Life Science Tools Amid Market Volatility In the shifting landscape of the life sciences sector, Bio-Techne Corporation (TECH) emerges as a resilient player, bolstered by st…
Bio-Techne Corporation: Resilience Amid Market Challenges Bio-Techne Corporation, a leader in the life sciences and tools (LST) sector, showcases a strong foundation despite recent market downturns, a…
Bio-Techne's Resilience Amid Market Challenges In recent assessments, RBC Capital has recognized Bio-Techne Corporation (TECH) as a standout entity within the life science and tools (LST) sector, desp…
Insider Activity Reflects Confidence in Bio-Techne’s Future In a recent development, Bio-Techne Corporation (TECH) showcases a significant insider transaction that may signal positive expectations for…
Bio-Techne Expands Its Influence in Life Sciences Through Strategic Conference Participation Bio-Techne Corporation, a prominent player in the life sciences sector, emphasizes its commitment to innova…
Bio-Techne Strengthens Industry Presence with Upcoming Conferences Bio-Techne Corporation, a prominent player in the life sciences sector, actively showcases its commitment to innovation and collabora…
Bio-Techne Strengthens Industry Presence with Upcoming Investor Conferences Bio-Techne Corporation, a prominent player in the global life sciences sector, announces its participation in a series of hi…
Bio-Techne's Growth Potential Amid Mixed Analyst Ratings In the past three months, Bio-Techne Corporation (TECH) encounters a spectrum of ratings from six analysts, revealing differing opinions about…
Bio-Techne's Mixed Analyst Ratings Reflect Industry Dynamics In recent months, Bio-Techne Corporation (TECH) has garnered a diverse array of ratings from six analysts, revealing differing opinions abo…
Navigating the Complex Landscape of Biotechnology: Bio-Techne's Position and Potential In the ever-evolving field of biotechnology, Bio-Techne Corporation stands out as a key player, providing essenti…
Innovative CAR T-Cell Manufacturing Platform Receives $300,000 G-Rex Grant In a significant advancement for gene and cell therapy, the Gates Institute's Translational Sciences Laboratory secures a $30…
Bio-Techne's Insider Transaction Signals Confidence in Biotechnology Innovations In a recent Securities and Exchange Commission (SEC) filing, Bio-Techne Corporation (TECH) board member John L. Higgins…
Bio-Techne Strengthens Commitment to Innovation Through Insider Transactions and Strategic Partnerships Bio-Techne Corporation (TECH) is currently making headlines as John L. Higgins, a member of its…
Bio-Techne Strengthens Commitment to Biotechnology Innovation with Insider Transaction Recent developments at Bio-Techne Corporation (TECH) highlight the company’s ongoing commitment to biotechnology…
Innovative Funding Fuels Cell Therapy Advancements at OverT Bio OverT Bio, a New York City-based company dedicated to cell therapy, recently secures a $120,000 G-Rex Grant from ScaleReadyTM, a collabo…